Dabrafenib (GSK2118436)

For research use only. Not for use in humans.

目录号：S2807 中文名称：达拉菲尼

Dabrafenib (GSK2118436) Chemical Structure

CAS No. 1195765-45-7

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1481.39	现货
5mg	RMB 733.64	现货
10mg	RMB 1056.75	现货
20mg	RMB 1394.46	现货
50mg	RMB 2235.84	现货
100mg	RMB 3261.37	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dabrafenib (GSK2118436)发表文献170篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202004707

PubMed: 32561648 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3205

PubMed: 33143299 ( click the link to review the publication )

Cancers (Basel), 2020, 22;12(2) pii: E512

PubMed: 32098410 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2981

PubMed: 33066704 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2020, 10.1111/pcmr.12932

PubMed: 33000894 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):973

PubMed: 33184267 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):156

PubMed: 32967672 ( click the link to review the publication )

ACS Infect Dis, 2020, acsinfecdis.0c00486

PubMed: 33183004 ( click the link to review the publication )
Sci Rep, 2020, 8;10(1):7826

PubMed: 32385388 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5557

PubMed: 32221312 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Biology (Basel), 2020, 9(8):E218

PubMed: 32785105 ( click the link to review the publication )

ESMO Open, 2020, 5(4):e000707

PubMed: 32817058 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Vet Pathol, 2020, 300985820967449

PubMed: 33205710 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3946

PubMed: 32770055 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(49):31105-31113

PubMed: 33229534 ( click the link to review the publication )

Acta Neuropathol Commun, 2020, 8(1):139

PubMed: 32811569 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cancer Res, 2019,

PubMed: 31362929 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )
Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )
Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )
Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )
Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )

Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Blood Adv, 2017, 30;1(24):2147-2160

PubMed: 29296862 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )
Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )

J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )
Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

产品安全说明书

Raf抑制剂选择性比较

生物活性

产品描述

Dabrafenib (GSK2118436)是一种突变型BRAFV600特异性抑制剂，无细胞试验中IC50为0.7 nM，作用于B-Raf(wt)和c-Raf效果分别低7和9倍。

靶点

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

体外研究

Dabrafenib对Raf激酶具有选择性，对B-Raf的活性比其它测试过的91%的激酶高400倍。 Dabrafenib抑制B-Raf^V600E激酶，导致ERK磷酸化降低和抑制细胞的增值，在特异性编码突变的B-Raf^V600E的癌细胞中细胞停滞在G1期。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	MWTLbY5ie2ViQYPzZZk>				NX\B[ZBKUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqeyC2YXfn[YQhSi2UYX[gWlYxOEVibYX0ZY51KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiY3:t[ZhxemW\|c3nu[{BETEN\|NzDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCkaX;0bY56dGG2ZXStUWVMKHC{b4TlbY4heGixc4Doc5J6dGG2aX;uJIJ6KEGucHjhV4Nz\WWwIHHzd4F6KHerdHigTWM2OCCxZjCwMlAxODdizszN	NUG4PFBTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzNpPkK0PVAxPjd\|PD;hQi=>
SK-MEL-28	M3f2emtqdmG\|ZTDBd5NigQ>?		NI\IdpAyKGh?		MY\Jcohq[mm2aX;uJI9nKEJvUnHmJHY3ODCHIH31eIFvfCCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gSXJMKHCqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFQh\|ryP	NVX5VldJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzNpPkK0PVAxPjd\|PD;hQi=>
HepG2	Mk[xT4lv[XOnIFHzd4F6				MmXZTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRiaX6gbJVu[W5iSHXwS\|Ih[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iRWLLJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMESg{txO	NIDD[Ik9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4Oyd-MkS5NFA3PzN:L3G+
COLO205	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorvTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRMkC1JINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFch\|ryP	NF;NT3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4Oyd-MkS5NFA3PzN:L3G+
HepG2	NFHIV4dHfW6ldHnvckBCe3OjeR?=		Ml;VOFUhdWmw	MVnEUXNQ	M1\2d2lvcGmkaYTpc44hd2ZiQXzrOUBqdiCWR1[tZoV1[S2\|dHnteYxifGWmIHj1cYFvKEincFeyJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKFOvYXSyJJBpd3OyaH;yfYxifGmxbjD0doVifGWmIH\vdkA1PSCvaX7zJJBzcW:{IITvJHRITi2kZYThJJN1cW23bHH0bY9vKG2nYYP1doVlKGGodHXyJFYxKG2rboOgZpkhd2S7c4PlfUBjdG:2IIPjZY5v\XJiYX7hcJl{cXNid3n0bEBKSzVyIH;mJFMvPyEQvF2=	NGjwN489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4Oyd-MkS5NFA3PzN:L3G+
HFF	NXjJO\|R[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnu2NVAh\|ryP	M2GxfVczKGh?	MVnEUXNQ	M{T0dmlvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCqdX3hckBJTkZiY3XscJMhcGG{Yn;ybY5oKHerbHSgeJlx\SCELWLh[kB4cXSqIFnDOVAhd2ZiMzFOwG0>	M3TuNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc{Lz5{NEmwNFY4OzxxYU6=
SK-MEL-28	NWK1TpZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVqxNEDPxE1?	M3\U[VczKGh?	NU\2U481TE2VTx?=	NXq5UFV2UW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSt[JJqfmWwIGPLMW1GVC1{ODDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMESzJO69VQ>?	NYjUdmhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
A375P-F11	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HjUlExKM7:TR?=	M2H3[FczKGh?	M4\NXGROW09?	M{TSdGlvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCDM{e1VE1HOTFiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB5MTFOwG0>	Mn3lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MALME-3M	MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\NSWs5OTBizszN	MkjmO\|IhcA>?	MXvEUXNQ	MkPOTWM2OD1zIH7N	M{XUOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
UACC-62	NGDCTHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;6NVAh\|ryP	MVW3NkBp	MXvEUXNQ	MV7JR\|UxRTFibl2=	M4W2eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
C32TG	NHflWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TS[FExKM7:TR?=	NV7sbol1PzJiaB?=	NYizVWxyTE2VTx?=	NGfxUVdKSzVyPUGgcm0>	NI\MXZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-MEL-1	NW\Nflc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPmNVAh\|ryP	Ml7JO\|IhcA>?	NHjpSVZFVVOR	M1TsSmlEPTB;MjDuUS=>	NVW3OIt{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
M14	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLXNVAh\|ryP	Mnj5O\|IhcA>?	MVfEUXNQ	Ml64TWM2OD1{IH7N	NXixSmxWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SK-MEL-28	NFW2ZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXGxNEDPxE1?	M4LqUVczKGh?	NWr3NVRSTE2VTx?=	MlHhTWM2OD1\|IH7N	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
A375	M3fY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnQdI93OTBizszN	NWjGUpc{PzJiaB?=	NVrF[opNTE2VTx?=	MV3JR\|UxRTRibl2=	M2nZc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
DU-4475	NFyzb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M133[VExKM7:TR?=	NHTU[ms4OiCq	MmfxSG1UVw>?	NYT4OINvUUN3ME21JI5O	NVrIOXlYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
UACC-257	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3oZ5Z7OTBizszN	NUnFcpZDPzJiaB?=	NVzi[XExTE2VTx?=	NVTM[XNmUUN3ME22JI5O	NWHDcXpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Colo 205	MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX2xNEDPxE1?	M3PSUFczKGh?	NVq1dFVkTE2VTx?=	MlK3TWM2OD15IH7N	NHmzXHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-MEL-3	M2r3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWj0U\|IxOTBizszN	MX[3NkBp	MW\EUXNQ	MYDJR\|UxRTdibl2=	MoDoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SH-4	M3Tn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTzUZgyOCEQvF2=	M365SVczKGh?	M4K2TWROW09?	MXLJR\|UxRThibl2=	M33k[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A101D	NGfMTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYqxNEDPxE1?	NXrNc\|lVPzJiaB?=	MVPEUXNQ	NITJXoZKSzVyPUmgcm0>	NGDXTZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
ES-2	NHTiSHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWD2[3hvOTBizszN	NX3mOW8{PzJiaB?=	MXrEUXNQ	MWnJR\|UxRTV\|IH7N	NWnPTXJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HT-29	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWT5eVQ3OTBizszN	MkPJO\|IhcA>?	NVLMSVU5TE2VTx?=	MofBTWM2OD14NjDuUS=>	NGW5dmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SW1417	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWe4c3UzOTBizszN	M{m0[\|czKGh?	MV3EUXNQ	NV\5eXFmUUN3ME2xOVghdk1?	NVX3c5JyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW872	NVfZcnVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWL4OIZFOTBizszN	MojxO\|IhcA>?	MYHEUXNQ	NEOybm1KSzVyPUO3O{BvVQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
RKO	M4PaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWmxNEDPxE1?	M2DkdVczKGh?	MlfJSG1UVw>?	MY\JR\|UxRTJwNUKyJO69VQ>?	NHTLdGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A673	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LQOFExKM7:TR?=	MYe3NkBp	M1XNUmROW09?	NWK4Z2tNUUN3ME2xNEDPxE1?	NHi1VVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
GCT	NYLoZpNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrXRlkyOCEQvF2=	M3nIWFczKGh?	M33oNGROW09?	MX3JR\|UxRTFyIN88US=>	NWjQOGl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
WM-115	Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnifJdLOTBizszN	M16xcVczKGh?	MnTTSG1UVw>?	NHnsUpJKSzVyPUWgcm0>	MnrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
YUMAC	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkn2NVAh\|ryP	NXrSV5N4PzJiaB?=	M1ez[mROW09?	MVzJR\|UxRTVibl2=	NV\SWXZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
OV-90	M{[2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrXeIR5OTBizszN	NU\TSWtxPzJiaB?=	M{XCeWROW09?	NYfVR5VTUUN3ME2yPUBvVQ>?	NFvKXYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H508	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPTNVAh\|ryP	MlLzO\|IhcA>?	MUXEUXNQ	MUjJR\|UxRTFyIN88US=>	MoH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MDA-MB-231	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFS5eXQyOCEQvF2=	NULHc4lQPzJiaB?=	M2\SWmROW09?	MXXJR\|UxRTFyIN88US=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW756	M1PqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYOxNEDPxE1?	M2XER\|czKGh?	MXLEUXNQ	NUfiPXhsUUN3ME2xNEDPxE1?	NXrMbm54RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW-837	NWPwOHBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\JNVAh\|ryP	MmOyO\|IhcA>?	M4XocGROW09?	MYrJR\|UxRTFyIN88US=>	NYHyb415RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
UMUC-3	NEnYS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGmyW2syOCEQvF2=	M{j5ZlczKGh?	M37DNWROW09?	MonWTWM2OD1zMDFOwG0>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
LS-174T	MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEW4c\|IyOCEQvF2=	MUe3NkBp	MkXYSG1UVw>?	NWHKe5pJUUN3ME2xNEDPxE1?	M3KwRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A549	NFP0cJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmflNVAh\|ryP	MnPyO\|IhcA>?	MWXEUXNQ	MYrJR\|UxRTFyIN88US=>	NFzscFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SHP-77	MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPWNVAh\|ryP	Mmi0O\|IhcA>?	M3zVWGROW09?	M3\D[WlEPTB;MUCg{txO	Mm\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW480	Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXONVAh\|ryP	MmnRO\|IhcA>?	MlP6SG1UVw>?	NXW4dYNMUUN3ME2xNEDPxE1?	MlLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
DLD-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXBdpoyOCEQvF2=	NF\UbWY4OiCq	NXnpc\|hmTE2VTx?=	NUHaNZZuUUN3ME2xNEDPxE1?	M1fwfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HCT-116	NE\XXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M325WFExKM7:TR?=	NHnHbG44OiCq	M4j4fGROW09?	MYHJR\|UxRTFyIN88US=>	NXLqc5d6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H747	MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3KVIRPOTBizszN	M{DnUVczKGh?	NFm3e2VFVVOR	NXTuSoZIUUN3ME2xNEDPxE1?	M2DSfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
T-84	M3LMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEKzUpMyOCEQvF2=	M33nOFczKGh?	M33lb2ROW09?	MWHJR\|UxRTFyIN88US=>	MoTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H460	NGnPPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX[xNEDPxE1?	NUi4cmk1PzJiaB?=	NF3tXY5FVVOR	NVniUodjUUN3ME2xNEDPxE1?	Mn;pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Calu-6	NX3mUVhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;iNHMyOCEQvF2=	MWO3NkBp	NWjT[41HTE2VTx?=	MXPJR\|UxRTFyIN88US=>	NG[2SlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HCC-2998	NGLmW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUH5SY5pOTBizszN	M2fQbVczKGh?	MlvBSG1UVw>?	M3nMSGlEPTB;MUCg{txO	NVvHXoVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
LS1034	NV;1eI91T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVf5UmJlOTBizszN	M3i2V\|czKGh?	M1:0cWROW09?	NFTYOWlKSzVyPUGwJO69VQ>?	NWC5NIZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
CHP-212	NHPaeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjobpA6OTBizszN	M1Ly[\|czKGh?	NWTm[5V4TE2VTx?=	MULJR\|UxRTFyIN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SK-N-AS	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXSxNEDPxE1?	MUi3NkBp	NXHUT5hMTE2VTx?=	MWDJR\|UxRTFyIN88US=>	NVvafZJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
BFTC-905	MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnH6NVAh\|ryP	MVS3NkBp	MUHEUXNQ	M4LBXmlEPTB;MUCg{txO	MnfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HuT78	NHXa[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vUOVExKM7:TR?=	NUizPYY{PzJiaB?=	M13DVGROW09?	M1:yTWlEPTB;NUKgcm0>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
RPMI-8226	M4ntZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37ybVExKM7:TR?=	NYTCR3h4PzJiaB?=	M33xXWROW09?	M3z1OmlEPTB;Mk[zJI5O	MnfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
BC-3	NX[yVVY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHwNVAh\|ryP	MoLwO\|IhcA>?	NXvNdFJXTE2VTx?=	M4njbGlEPTB;Mke3JI5O	MmHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
ACHN	NGXEfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXWxNEDPxE1?	NUX2eINiPzJiaB?=	NVrQXVJlTE2VTx?=	NEPRdIRKSzVyPUK5OEBvVQ>?	NV3jR\|ltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
JRT3-T35	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvQNVAh\|ryP	MXO3NkBp	NGfRdXdFVVOR	M325cGlEPTB;Mkm1JI5O	M3\oUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-MES-1	NY\sVWtqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MonINVAh\|ryP	NULqWXNsPzJiaB?=	MmXrSG1UVw>?	NVzKOZFFUUN3ME2zNlkhdk1?	MmrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
CESS	NHPjTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWixNEDPxE1?	MUS3NkBp	MUTEUXNQ	Ml7ITWM2OD12OUegcm0>	NIX1dZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
H4	NEDkO\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\DfmwyOCEQvF2=	MUe3NkBp	MV;EUXNQ	NYH0c5RrUUN3ME22NVkhdk1?	NEHL[Gs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
BC-1	NU\sdppiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrYfJg3OTBizszN	NUPJV4xqPzJiaB?=	M2K3NGROW09?	Mmm2TWM2OD15MESgcm0>	M4XlcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
DB	MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfjV2UyOCEQvF2=	NWj6d2ppPzJiaB?=	MWnEUXNQ	MUHJR\|UxRTh5MzDuUS=>	NHvMPYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
RPMI-6666	NUTNZZMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX6xNEDPxE1?	NXnSN5BIPzJiaB?=	MnGwSG1UVw>?	NXnQfYNyUUN3ME25Nlghdk1?	M2TocVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
MC/CAR	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnzNVAh\|ryP	Mkm2O\|IhcA>?	M2SwS2ROW09?	Mnj0TWM2OD1zLkCwNkDPxE1?	NGTUR2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SNU-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV[2WI5HOTBizszN	NIqzXFM4OiCq	MVvEUXNQ	MkLITWM2OD1zLkWwNUDPxE1?	NFrzNHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CEM/C1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYe2fIt{OTBizszN	MlPoO\|IhcA>?	M4Xs[WROW09?	M1;0UmlEPTB;MT63O\|Mh\|ryP	M1nocVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
GDM-1	NESycllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInrfW8yOCEQvF2=	M3;TXFczKGh?	NUDIPHhFTE2VTx?=	NF;SRYtKSzVyPUGuPVk4KM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HT-1080	MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEKxXIMyOCEQvF2=	M2G5XlczKGh?	MYTEUXNQ	NE\QOZNKSzVyPUKuNFA1KM7:TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HL-60	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYCxNEDPxE1?	Mo\6O\|IhcA>?	NVfvV4JZTE2VTx?=	M{HXcWlEPTB;Mj6xO\|gh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
C3A	Mkj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnFNVAh\|ryP	NWHGWZA6PzJiaB?=	NXP6WIJFTE2VTx?=	M2X3NGlEPTB;NT60NVQh\|ryP	NEOzd4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
MES-SA	M1u5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXhRVNuOTBizszN	M4jpZ\|czKGh?	NWXFcVRTTE2VTx?=	M{\0OGlEPTB;Nj65PFkh\|ryP	Mlf5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
22Rv1	NUH6NnNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojUNVAh\|ryP	NETXb3c4OiCq	NGPDeZBFVVOR	MWPJR\|UxRTFyIN88US=>	NUTE[5JwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
647-V	NWr0RoxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXMeG4yOCEQvF2=	M2jUeFczKGh?	NWrRXFMxTE2VTx?=	M3Xh[WlEPTB;MUCg{txO	Ml7lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
786-O	NYrrOZlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXQXIpDOTBizszN	NGjBVpc4OiCq	NW[2fXV3TE2VTx?=	MoXaTWM2OD1zMDFOwG0>	M2rKUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A172	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU[xNEDPxE1?	MonWO\|IhcA>?	NFrEVZlFVVOR	MV7JR\|UxRTFyIN88US=>	MlfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
A204	MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NED2[YIyOCEQvF2=	M3:zN\|czKGh?	MYDEUXNQ	M1HVb2lEPTB;MUCg{txO	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
A427	Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{P4fFExKM7:TR?=	NEn4VmM4OiCq	MVjEUXNQ	Ml\zTWM2OD1zMDFOwG0>	NGrUXWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A431	NWnnTJVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ro[lExKM7:TR?=	MlT1O\|IhcA>?	M1Xv[GROW09?	M3vBT2lEPTB;MUCg{txO	M37TNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A2780	Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXX6TmRVOTBizszN	MkC1O\|IhcA>?	MnTrSG1UVw>?	M2LPdWlEPTB;MUCg{txO	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
ARH-77	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfqUG4yOCEQvF2=	MVK3NkBp	Mln2SG1UVw>?	NH\m[ZNKSzVyPUGwJO69VQ>?	NHrvTYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Be(2)C	M3PVVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYKxNEDPxE1?	NG\JTHU4OiCq	MXXEUXNQ	MnH6TWM2OD1zMDFOwG0>	M{HTTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
BT-20	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3rPWIyOCEQvF2=	MV23NkBp	M4nBfmROW09?	NUD5dJNtUUN3ME2xNEDPxE1?	NFPxUFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
BxPc3	NF3NcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\aVlExKM7:TR?=	NXzCcWI{PzJiaB?=	NVP2bWpJTE2VTx?=	MUTJR\|UxRTFyIN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
C-4 I	NEP1bGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWKxNEDPxE1?	NYDWXZZsPzJiaB?=	NInnclNFVVOR	MmnsTWM2OD1zMDFOwG0>	M3iyUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
C33A	M4rkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzuOpJzOTBizszN	MmHiO\|IhcA>?	M{L6WGROW09?	MlPMTWM2OD1zMDFOwG0>	M3G2SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
CAL-27	M4DOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PaO\|ExKM7:TR?=	MUe3NkBp	M3HtW2ROW09?	MXXJR\|UxRTFyIN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
CAL-62	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrZWIE{OTBizszN	MmfnO\|IhcA>?	NGDqNWxFVVOR	MYnJR\|UxRTFyIN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Calu-3	M3fMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mof4NVAh\|ryP	Ml3nO\|IhcA>?	NV3EZpZLTE2VTx?=	MUTJR\|UxRTFyIN88US=>	NYi2THFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
CaOV3	MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPZV2t4OTBizszN	NFf0WIU4OiCq	M4LVV2ROW09?	MV3JR\|UxRTFyIN88US=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
CGTHW1	MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX:xNEDPxE1?	NVXMfpVsPzJiaB?=	NXLKbWVPTE2VTx?=	MX7JR\|UxRTFyIN88US=>	NYnKOHlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
CHL-1	NX3OW2Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrPU4xPOTBizszN	MXW3NkBp	NWrMXY46TE2VTx?=	Mm\0TWM2OD1zMDFOwG0>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Colo320DM	MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\RNVAh\|ryP	MVe3NkBp	NVyxcXFJTE2VTx?=	NVP0XGFQUUN3ME2xNEDPxE1?	NUXhZ2xbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Colo704	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTROXYyOCEQvF2=	MkjtO\|IhcA>?	MkjHSG1UVw>?	NFjv[3hKSzVyPUGwJO69VQ>?	NHvkcoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
COR-L23	MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LaOlExKM7:TR?=	M2HSTFczKGh?	NILncIxFVVOR	NHT2SmNKSzVyPUGwJO69VQ>?	M3PR[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
CRO-AP2	M2\hOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XpVVExKM7:TR?=	NYnHfVd2PzJiaB?=	NEjPN5BFVVOR	MWfJR\|UxRTFyIN88US=>	M172WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
Daudi	MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoL5NVAh\|ryP	MUG3NkBp	NFvRR4dFVVOR	M3zwUWlEPTB;MUCg{txO	MlTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
DOTC 24510	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnPNYkyOCEQvF2=	MmXWO\|IhcA>?	NH;CTIVFVVOR	NXy2NZE3UUN3ME2xNEDPxE1?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
DU-145	NFrHcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\u[IMyOCEQvF2=	Mn;kO\|IhcA>?	MmPaSG1UVw>?	Mk\rTWM2OD1zMDFOwG0>	NIrZO\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
EB-3	M1zp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjOcJcyOCEQvF2=	MX63NkBp	NWHafI9rTE2VTx?=	NY\p[4Z[UUN3ME2xNEDPxE1?	NHHGO5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
EFM-19	NEP0SYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLzfII5OTBizszN	M{DobVczKGh?	NHLqZpNFVVOR	NEW3V2tKSzVyPUGwJO69VQ>?	NG[5VHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
EKVX	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVKxNEDPxE1?	MkPBO\|IhcA>?	M{X4WGROW09?	MoK2TWM2OD1zMDFOwG0>	NFq4XpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
FaDu	MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n3e\|ExKM7:TR?=	NGqwSHA4OiCq	NIPvZmxFVVOR	MmX4TWM2OD1zMDFOwG0>	MlzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
G401	NWnIc3ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\kNVAh\|ryP	NI[wPWk4OiCq	M37U[2ROW09?	NH34SYdKSzVyPUGwJO69VQ>?	NWrQfVFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HCC-70	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4LIflExKM7:TR?=	NUDIXZJ{PzJiaB?=	NGfuZ3BFVVOR	MVfJR\|UxRTFyIN88US=>	NX\OV4xWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HCC-1954	M{fUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfuOlJ1OTBizszN	MnHJO\|IhcA>?	MWTEUXNQ	MXTJR\|UxRTFyIN88US=>	M{nF[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
Hela	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\LNHoyOCEQvF2=	M4DTTlczKGh?	NEDkZlRFVVOR	MU\JR\|UxRTFyIN88US=>	Mmr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Hep3B	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnHWJoyOCEQvF2=	M4D1fFczKGh?	MlT4SG1UVw>?	NGfiXlBKSzVyPUGwJO69VQ>?	MoPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HMCB	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVOxNEDPxE1?	NWDSepRsPzJiaB?=	NX:1XYRETE2VTx?=	MV\JR\|UxRTFyIN88US=>	NFrKO3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HN5	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfZN3FzOTBizszN	MYS3NkBp	M{nDcmROW09?	NUPNToN2UUN3ME2xNEDPxE1?	MnL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HOS	M1TlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWWxNEDPxE1?	NWDRc2t{PzJiaB?=	MYHEUXNQ	NHvWSodKSzVyPUGwJO69VQ>?	Mo\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HPAF-II	NXKwblBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7qZXBTOTBizszN	M2LTTFczKGh?	M2WxW2ROW09?	NVrpcVZOUUN3ME2xNEDPxE1?	NGHofGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Hs746.T	NHzhNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH73O2IyOCEQvF2=	MYS3NkBp	NHHGSVBFVVOR	MVHJR\|UxRTFyIN88US=>	M2HHUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HT	NY[0Z3NuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYmxNEDPxE1?	M2fHR\|czKGh?	MYPEUXNQ	NEf6doxKSzVyPUGwJO69VQ>?	Ml7OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HT-3	NVPiemZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;L[FExKM7:TR?=	NFLLOYc4OiCq	MlXySG1UVw>?	NGXnO2lKSzVyPUGwJO69VQ>?	NWfjN5NNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HuNS-1	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3qWHcyOCEQvF2=	M4nlVlczKGh?	NEfteXFFVVOR	MkXOTWM2OD1zMDFOwG0>	M1HLblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
IGROV1	M{jB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDPNVAh\|ryP	MnjyO\|IhcA>?	NVHSO3cxTE2VTx?=	NHW5eppKSzVyPUGwJO69VQ>?	NXz6b\|dORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
J82	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFriWVUyOCEQvF2=	MVi3NkBp	NIXsfplFVVOR	MVXJR\|UxRTFyIN88US=>	NGnJSog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
JM1	MnHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjFNVAh\|ryP	MmLpO\|IhcA>?	Mn7tSG1UVw>?	NXTLb2NHUUN3ME2xNEDPxE1?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Kato III	NFTEdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTONVAh\|ryP	MYK3NkBp	M2Lrb2ROW09?	NHTxcmtKSzVyPUGwJO69VQ>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
KHOS-240S	M4DYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkC1NVAh\|ryP	MVy3NkBp	NWrVWm42TE2VTx?=	MorsTWM2OD1zMDFOwG0>	M3P4bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
KM-12	NWLSWXJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIq4eI0yOCEQvF2=	Mn;zO\|IhcA>?	NXPqbnQyTE2VTx?=	NXrsR2k{UUN3ME2xNEDPxE1?	NVKxPVdWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
KPL-1	NIHNW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;4WVJ3OTBizszN	MoDMO\|IhcA>?	MWrEUXNQ	NXrKUoIyUUN3ME2xNEDPxE1?	MkK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
KYSE-30	MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jmZ\|ExKM7:TR?=	NFTQXXc4OiCq	M1e2bGROW09?	NF3LTpJKSzVyPUGwJO69VQ>?	NHXSPXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
LNCaP	NWPudpYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX6xNEDPxE1?	NYewPJh6PzJiaB?=	MXLEUXNQ	NXS1OZd4UUN3ME2xNEDPxE1?	NVTnc4YzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
MCF-7	NX\qRYpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHTTWJpOTBizszN	NF3NeY44OiCq	MU\EUXNQ	NHKxcGpKSzVyPUGwJO69VQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
MC-IXC	MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXWxNEDPxE1?	MUm3NkBp	NIrEb3NFVVOR	Mkm2TWM2OD1zMDFOwG0>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
MDA-MB-175 VII	NIGzd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUOxNEDPxE1?	NWn3SYY3PzJiaB?=	M2XlTGROW09?	NXrPVFhVUUN3ME2xNEDPxE1?	MnHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MDA-MB-468	MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljaNVAh\|ryP	NXjDW4dZPzJiaB?=	NI\vcFJFVVOR	MYHJR\|UxRTFyIN88US=>	MojvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MiaPaCa	NF\NeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWn3[45TOTBizszN	MkOwO\|IhcA>?	NF;IOopFVVOR	NXT0WJBLUUN3ME2xNEDPxE1?	M1vD[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
Molt-4	NVPndnRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYG5Z5k4OTBizszN	MoDBO\|IhcA>?	NWHZcXNWTE2VTx?=	NXjoUYFXUUN3ME2xNEDPxE1?	NWri[5BERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-ADR/RES	NEnWeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1Sw[lExKM7:TR?=	M1XvUVczKGh?	MUTEUXNQ	M4jHXmlEPTB;MUCg{txO	MmPUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H69	NFnaN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlv0NVAh\|ryP	NXn2[m46PzJiaB?=	MnrXSG1UVw>?	M3nGVGlEPTB;MUCg{txO	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H82	MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjPUYgyOCEQvF2=	MmPYO\|IhcA>?	NXnlcpg3TE2VTx?=	NF;sWGZKSzVyPUGwJO69VQ>?	NILkXHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-N87	NWS5flhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUmxNEDPxE1?	MVy3NkBp	NGjJfpJFVVOR	Mn3uTWM2OD1zMDFOwG0>	MnT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H146	M1rLUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rOVVExKM7:TR?=	M3[xeFczKGh?	MVXEUXNQ	NVPL[mdIUUN3ME2xNEDPxE1?	NG\DbWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H157	NFXxSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjmNVAh\|ryP	M4fMd\|czKGh?	M2n2bmROW09?	M{HrbmlEPTB;MUCg{txO	NYGwNIQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H187	NILYUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{S5[lExKM7:TR?=	M2fZcFczKGh?	NVnjdIJoTE2VTx?=	NIWyc4hKSzVyPUGwJO69VQ>?	MkPpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H209	NEXMSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jUfVExKM7:TR?=	MmrpO\|IhcA>?	NGjHd2hFVVOR	NXyxcopkUUN3ME2xNEDPxE1?	NFTVUZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H226	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPZbJEyOCEQvF2=	NYTGO20zPzJiaB?=	M2nocWROW09?	MVfJR\|UxRTFyIN88US=>	NVzSUmdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H292	NEn1VW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;Y[VExKM7:TR?=	NIiwfpg4OiCq	M2PmeWROW09?	MVTJR\|UxRTFyIN88US=>	M2fsfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H322	MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjpNpVjOTBizszN	MXy3NkBp	Mk\0SG1UVw>?	NUPxVFMzUUN3ME2xNEDPxE1?	NHT5NGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H358	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHPvZW4yOCEQvF2=	MmW4O\|IhcA>?	NGTwUFZFVVOR	MmqzTWM2OD1zMDFOwG0>	NFL4U5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H520	Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYCxNEDPxE1?	NYLvSXhzPzJiaB?=	MlexSG1UVw>?	M3zCN2lEPTB;MUCg{txO	Mn71QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H526	M1rpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUmxNEDPxE1?	NX3wdG9XPzJiaB?=	M1LIOGROW09?	NYHaSYRpUUN3ME2xNEDPxE1?	M4fufFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H630	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXjNVAh\|ryP	NY\BbYQ2PzJiaB?=	NFX3UXRFVVOR	NFvKeIxKSzVyPUGwJO69VQ>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H661	NYriNZF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH31[ogyOCEQvF2=	MnvEO\|IhcA>?	M1Wyc2ROW09?	MVjJR\|UxRTFyIN88US=>	M3\SVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H716	MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HZ[VExKM7:TR?=	NGnucng4OiCq	MnTSSG1UVw>?	Mnn6TWM2OD1zMDFOwG0>	NHnscGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H1563	MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWSxNEDPxE1?	MoTHO\|IhcA>?	MlzySG1UVw>?	NIXNfoVKSzVyPUGwJO69VQ>?	NEXHTHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H1792	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYm3OINuOTBizszN	MV[3NkBp	NGXpTodFVVOR	NUGy[45vUUN3ME2xNEDPxE1?	NGnsSFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H2030	NFXwb\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXGxNEDPxE1?	MU[3NkBp	MknpSG1UVw>?	NY\tdZpoUUN3ME2xNEDPxE1?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H2052	Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnobGEyOCEQvF2=	M1\kW\|czKGh?	NF\reIRFVVOR	Mn;ITWM2OD1zMDFOwG0>	M{LvVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H2122	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXqxNEDPxE1?	NWToWpFUPzJiaB?=	MVPEUXNQ	NYfTbWtuUUN3ME2xNEDPxE1?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H2228	NWfDbplGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoH2NVAh\|ryP	NYGzXoNjPzJiaB?=	MVvEUXNQ	NH\rWnJKSzVyPUGwJO69VQ>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
OE-19	MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYSxNEDPxE1?	MX23NkBp	NWG2[HRkTE2VTx?=	MVjJR\|UxRTFyIN88US=>	NF3INYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
OE-21	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVyxNEDPxE1?	MlXYO\|IhcA>?	MXTEUXNQ	M3\P[mlEPTB;MUCg{txO	NUHiUGdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
OE-33	NV20OXFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTkWYsyOCEQvF2=	MoX0O\|IhcA>?	MVTEUXNQ	Mn\2TWM2OD1zMDFOwG0>	NIfSfIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
OVCAR-3	M4PFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFH6cncyOCEQvF2=	NGG3bWU4OiCq	MoXxSG1UVw>?	M33sUmlEPTB;MUCg{txO	MkWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
OVCAR-4	M1yz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPLUZpDOTBizszN	MWO3NkBp	NYTFVmY6TE2VTx?=	MX\JR\|UxRTFyIN88US=>	M3nUdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OVCAR-5	NXHtUGQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7obmgyOCEQvF2=	NXnzdGUyPzJiaB?=	MVvEUXNQ	NEfQcXBKSzVyPUGwJO69VQ>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
P3HR-1	MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXexNEDPxE1?	M1LXSlczKGh?	NFzlOHRFVVOR	MoPHTWM2OD1zMDFOwG0>	NWLoO4I{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
PC-3	MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX6xNEDPxE1?	NF;wUWg4OiCq	NHPobZNFVVOR	NH:zbYdKSzVyPUGwJO69VQ>?	NXO5V2JDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Raji	NYn0UVQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY[xNEDPxE1?	MlLZO\|IhcA>?	MV3EUXNQ	MnfETWM2OD1zMDFOwG0>	M17ae\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
RD	NHG5TGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWr4S4xbOTBizszN	NGHjVm44OiCq	M1\jO2ROW09?	NXXOeWlIUUN3ME2xNEDPxE1?	NWrz[5o2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
RD-ES	NH7hRpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLWNVAh\|ryP	M322TlczKGh?	M2ribWROW09?	NUKwV3F2UUN3ME2xNEDPxE1?	M3;QbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
RL	M1noTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVWxNEDPxE1?	NHTtc2Q4OiCq	MUnEUXNQ	M1zTN2lEPTB;MUCg{txO	M1vyc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SaOS2	NWrlXJp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TuXVExKM7:TR?=	NEnLWnM4OiCq	NYfMXGRRTE2VTx?=	MXTJR\|UxRTFyIN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SCC-9	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn:3NVAh\|ryP	Mn3EO\|IhcA>?	MUXEUXNQ	MVzJR\|UxRTFyIN88US=>	M{P1ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SCC-12	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYGxNEDPxE1?	NUO0RnFoPzJiaB?=	MWDEUXNQ	M2XBXGlEPTB;MUCg{txO	NIjISpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SCC-13	NE\aT\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXuw[Y5QOTBizszN	MV[3NkBp	NIjOVmFFVVOR	NF;tPXlKSzVyPUGwJO69VQ>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SCC-15	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPNXFAyOCEQvF2=	M17NNVczKGh?	MljmSG1UVw>?	NVntdVJMUUN3ME2xNEDPxE1?	MkPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SCC-25	NUTYRWhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUCxNEDPxE1?	MUK3NkBp	MX7EUXNQ	NGTzSGhKSzVyPUGwJO69VQ>?	NV\CNGh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SCLC-3	NXf2WGdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\KWFExKM7:TR?=	NVLYUop4PzJiaB?=	MnzVSG1UVw>?	NVPVO\|lMUUN3ME2xNEDPxE1?	NFH5PXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SF-268	M1j3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nsb\|ExKM7:TR?=	Mlj3O\|IhcA>?	NF[5bmJFVVOR	NWHPSJBiUUN3ME2xNEDPxE1?	M{DMN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SF-295	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHflb2UyOCEQvF2=	M1z2XVczKGh?	MlPCSG1UVw>?	MYDJR\|UxRTFyIN88US=>	NGrSXpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SJRH30	M1HN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7mbIoyOCEQvF2=	MmjBO\|IhcA>?	NYrDb455TE2VTx?=	MVnJR\|UxRTFyIN88US=>	NUHpSHF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SK-BR-3	M4nXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLZNVAh\|ryP	Ml;IO\|IhcA>?	NH35SFNFVVOR	NFHze2xKSzVyPUGwJO69VQ>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SK-LMS-1	Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVK1SoJPOTBizszN	MkP2O\|IhcA>?	Mn64SG1UVw>?	NInyZnVKSzVyPUGwJO69VQ>?	MnX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SK-N-DZ	MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHaNVAh\|ryP	MVG3NkBp	M4f5VWROW09?	MXvJR\|UxRTFyIN88US=>	NXzSfHRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SK-N-F1	NUm3d2NGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHlSG0yOCEQvF2=	MorXO\|IhcA>?	M2D1bGROW09?	MlnkTWM2OD1zMDFOwG0>	NI\XPVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SKOV-3	NIO0NnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XYUVExKM7:TR?=	NEfteVA4OiCq	MXPEUXNQ	NXLMSFNjUUN3ME2xNEDPxE1?	NGjobnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-UT-1	NH\GOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TkT\|ExKM7:TR?=	MYG3NkBp	NYH5boZxTE2VTx?=	M4j1eWlEPTB;MUCg{txO	MorZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SN12C	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXwNVAh\|ryP	NHXGVYU4OiCq	NVfmVplFTE2VTx?=	NH;uNIFKSzVyPUGwJO69VQ>?	M{HBdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SNB-19	NYflNVd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFL4XZkyOCEQvF2=	NH;TdnY4OiCq	NHPV[YVFVVOR	NGXQcW5KSzVyPUGwJO69VQ>?	M2m2SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SNU-5	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmD6NVAh\|ryP	NEeyeok4OiCq	Mli2SG1UVw>?	M13oUmlEPTB;MUCg{txO	NGHtflI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SNU-16	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIWwcFUyOCEQvF2=	MlHxO\|IhcA>?	MV;EUXNQ	MnjKTWM2OD1zMDFOwG0>	MmTMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SNU-398	NYHueIZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHi4dXgyOCEQvF2=	NEPxbnQ4OiCq	MoLUSG1UVw>?	MlfpTWM2OD1zMDFOwG0>	NHfpR5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SNU-449	Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3f5[\|ExKM7:TR?=	M2DEflczKGh?	NFfMV4FFVVOR	NHq4cY9KSzVyPUGwJO69VQ>?	NHXlVYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SR	NGWz[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUOxNEDPxE1?	M1HONVczKGh?	Moq1SG1UVw>?	NIXnOoNKSzVyPUGwJO69VQ>?	MoqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
ST486	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXHNVAh\|ryP	MofBO\|IhcA>?	MXjEUXNQ	MlXGTWM2OD1zMDFOwG0>	Ml;aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW579	NF;hTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XHbVExKM7:TR?=	NF7WV284OiCq	MnexSG1UVw>?	NGf1fVRKSzVyPUGwJO69VQ>?	NUDYVnZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW684	NF63SVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fKeFExKM7:TR?=	NGSyfGo4OiCq	NU\Lb2hSTE2VTx?=	NGX5UFZKSzVyPUGwJO69VQ>?	M{SxSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW-780	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLrUI4yOCEQvF2=	MmPHO\|IhcA>?	NVvwdmZUTE2VTx?=	NVXI[Ip{UUN3ME2xNEDPxE1?	M3\sZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW900	Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\KVI4yOCEQvF2=	MXe3NkBp	M{XaTWROW09?	M1XndmlEPTB;MUCg{txO	Mn;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW1088	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHmNVAh\|ryP	Mn7oO\|IhcA>?	MVfEUXNQ	MXfJR\|UxRTFyIN88US=>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW1463	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnQNVAh\|ryP	MXu3NkBp	MWLEUXNQ	NWfZZo1EUUN3ME2xNEDPxE1?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SW1990	NIK3eHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlToNVAh\|ryP	NVe2ZYt1PzJiaB?=	M{njTmROW09?	NFXldGJKSzVyPUGwJO69VQ>?	NV3Eb2xORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
T47D	NVLNbW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXqxNEDPxE1?	NVjkSFV2PzJiaB?=	NXrCeWFlTE2VTx?=	M1eyR2lEPTB;MUCg{txO	M2racVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
TE381.T	NWLiSVljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVX2PJloOTBizszN	NF24R3Q4OiCq	MmeySG1UVw>?	NVjXPXFkUUN3ME2xNEDPxE1?	M{XPN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
TK-10	MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzWbJQyOCEQvF2=	NGPzTno4OiCq	M1\1ZmROW09?	MmfaTWM2OD1zMDFOwG0>	M3PWU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
U2OS	NGrpPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rPblExKM7:TR?=	NY\u[ZVxPzJiaB?=	M3;RXWROW09?	MnHxTWM2OD1zMDFOwG0>	MnLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
U251	NVnPZ2lOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrNRlkyOCEQvF2=	M3XXelczKGh?	NEjReIlFVVOR	NFS1fmlKSzVyPUGwJO69VQ>?	NFTCZVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
UACC-812	MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3L5W\|ExKM7:TR?=	MV:3NkBp	M{ftdWROW09?	NF22VGJKSzVyPUGwJO69VQ>?	NXr6PGNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
YAPC	NVnxXGZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVqxNEDPxE1?	MUm3NkBp	NUTHUGsyTE2VTx?=	NH7Yb2xKSzVyPUGwJO69VQ>?	NUTZVlhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
ZR-75-1	NYrrcIs2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vWT\|ExKM7:TR?=	M2nkNlczKGh?	NFfQNlBFVVOR	Mkm0TWM2OD1zMDFOwG0>	NWrzcW9zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
A375	NUTXdZZbTnWwY4Tpc44h[XO\|YYm=	NGH1R44yNjJizszN	NWnGV4ZtPCCq	NVLaXYNJTE2VTx?=	M{SwUGlvcGmkaYTpc44hd2ZicHjvd5Bpd3K7bHH0bY9vKG:oIF3FT{whTVKNLDDhcoQhWz[S	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN6OUS3NUc,OjJ\|OEm0O\|E9N2F-
YUSIT1	NH7vR5RHfW6ldHnvckBie3OjeR?=			NXPMZodmTE2VTx?=	M{L2cZJm\HWlZXSgd4Vve2m2aY\peJkhf2m2aDDJR\|UxKD5iMD61JO69VQ>?	NV;yVmRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzPFk1PzFpPkKyN\|g6PDdzPD;hQi=>
MeWo	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MXfEUXNQ	M3LERmlEPTBiPTC5PFchdk1?	MlLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUi1NlQoRjJ4MEG4OVI1RC:jPh?=
WiDr	M1e4ZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MkTQSG1UVw>?	NGHIUnBKSzVyIE2gO\|Yhdk1?	MlnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUi1NlQoRjJ4MEG4OVI1RC:jPh?=
Colo-205	NWnKenJQTnWwY4Tpc44h[XO\|YYm=	NXjYWXQ5OSEQvF2=	M3WweVQh\A>?	MmrFSG1UVw>?	NVXTcFdjUW6mdXPl[EBiKGirZ3jsfUBkd22yYYLhZoxmKGOxbYDhZ5Rqd25icHjlco91gXCn	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN6MUG1Nkc,OjV\|OEGxOVI9N2F-
RBW-1	NWfaRXVnTnWwY4Tpc44h[XO\|YYm=	M{LLWlEh\|ryP		NH[4PWVFVVOR	MX;Oc{Bz\WS3Y4Tpc44hd2ZiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	NHTYRoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OVY6OCd-MkS4PFU3QTB:L3G+
RBO-1	MmTDSpVv[3Srb36gZZN{[Xl?	NEHH[WIyKM7:TR?=		M2PlO2ROW09?	MXPJcohq[mm2aX;uJI9nKE2nazCxM\|IheGixc4Doc5J6dGG2aX;u	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NU[5NEc,OjR6OEW2PVA9N2F-
RBO-2	MUXGeY5kfGmxbjDhd5NigQ>?	NH3GUmoyKM7:TR?=		MVjEUXNQ	MYrJcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NU[5NEc,OjR6OEW2PVA9N2F-
RBOW	M2fqemZ2dmO2aX;uJIF{e2G7	M3q5WlEh\|ryP		NXy0fIFbTE2VTx?=	MU\Jcohq[mm2aX;uJI9nKCCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NU[5NEc,OjR6OEW2PVA9N2F-
M257	NVjBZo9bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXXVnRLOTByIH7N	M{\lb\|czKGh?		NInxbphFd2W\|IH7veEBqdmirYnn0JJBzd2yrZnXyZZRqd25ib3[gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	NHrPS5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxO\|Q1Pid-MkOzNVc1PDZ:L3G+
LCP	MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3kNVAxKG6P	MVS3NkBp		MmjpTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJI9nKEyFUDDj[YxtKGijcnLveZJqdmdiQmLBSkBXPjByUjDteZRidnSjdHnvci=>	MoW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUe0OFYoRjJ\|M{G3OFQ3RC:jPh?=
WM266	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnOVGZjOTByIH7N	M3fFWVczKGh?		NVG5boIxUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFFFKG23dHHueIF1cW:w	M{S1bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G3OFQ3Lz5{M{OxO\|Q1PjxxYU6=
M257	MmGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnpVVcyODBibl2=	NHzZXm84OiCq		NFXEe25Fd2W\|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzN{S0Okc,OjN\|MUe0OFY9N2F-
LCP	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfwUIsyODBibl2=	MnHzO\|IhcA>?		M2nodWlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDMR3Ah[2WubDDoZZJjd3W{aX7nJGJTSUZiVk[wNHIhdXW2YX70ZZRqd25?	M1LhdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G3OFQ3Lz5{M{OxO\|Q1PjxxYU6=
WM266	M2LLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnTVGMyODBibl2=	MVe3NkBp		NYru[lJwUW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJHdOOjZ4IHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCGIH31eIFvfGG2aX;u	M4nDd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{G3OFQ3Lz5{M{OxO\|Q1PjxxYU6=
A375	MYPCVmFHKGOxbYDleIl1cX[nIHLpcoRqdmdiYYPzZZk>		MlLhNVUhdWmw		M{Tye2lEPTBiPTCwMlAxPiEQvF2=	MlrBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkW4NFQoRjJ3OU[1PFA1RC:jPh?=
A375	NYDqSIVlTnWwY4Tpc44h[XO\|YYm=		NF\Mblc4OiCq		MmDzTWM2OCB;IECuNFEyKM7:TR?=	NWDMbXJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlU5ODRpPkK1PVY2QDB2PD;hQi=>
A375	M1PVUWFTSUZiY3;tdIV1cXSrdnWgZolv\GmwZzDhd5NigQ>?		NVy2ZXA1OTVibXnu		NETibJBKSzVyIE2gNE4xOjZizszN	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4NUiwOEc,OjV7NkW4NFQ9N2F-
A375	NFzTb\|dEWkGIIHPvcZBmfGm2aY\lJIJqdmSrbnegZZN{[Xl?		MnjSNVUhdWmw		M3O1SmlEPTBiPTCwMlE2KM7:TR?=	NHHDWlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2OVgxPCd-MkW5OlU5ODR:L3G+
HCT116	NHX1T45HfW6ldHnvckBie3OjeR?=				MXPJR\|UxKD1iNT64PEDPxE1?	MleyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkW4NFQoRjJ3OU[1PFA1RC:jPh?=
A375	NYPtOJRvTnWwY4Tpc44h[XO\|YYm=		NYLSVYI2OSCq		NH3HT\|lKSzVyIE2gNE4xODFizszN	NXOzcm4yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFU3PzJpPkK3NFg2Pjd{PD;hQi=>
MIAPaCa2	MVTGeY5kfGmxbjDhd5NigQ>?		MnHWNUBp		MVXFR\|UxKD1iMD61Nlkh\|ryP	M1H2SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEi1OlczLz5{N{C4OVY4OjxxYU6=
A375	NGjMVIVHfW6ldHnvckBie3OjeR?=				M3;6NmlEPTBiPTCwMlAxPCEQvF2=	NIfm[Y89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2NVgzPyd-Mkm0OlE5Ojd:L3G+
SK-MEL-28	NGToXpJEgXSxdH;4bYNqfHliYYPzZZk>		NWDSdGsyPzJiaB?=		NGLN[IVKSzVyIE2gNE4xPDNizszN	MmPwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NkG4NlcoRjJ7NE[xPFI4RC:jPh?=
Sf9	NHfxZVlHfW6ldHnvckBie3OjeR?=		NVnkUplQPjBibXnu		NVPSTIo{UUN3MDC9JFAvODB7IN88US=>	M1Hz[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVM4Lz5{N{e3OFE{PzxxYU6=
SK-MEL-28	NF7iUnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVz5NFNKPDhiaB?=		NY\3NI9KT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI5KGOnbHzzJIhiemKxcnnu[{BDWkGIIG[2NFBGKG23dHHueEBu\WG\|dYLl[EBi\nSncjC0PEBpenNicnXzZZp2emmwIHHzd4F6	MmezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxN\|coRjJ5N{e0NVM4RC:jPh?=
SK-MEL-28	MmDPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWG0PEBp		NH\4e2VIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNlgh[2WubIOgbIFz[m:{aX7nJGJTSUZiVk[wNGUhdXW2YX70JJBz\WmwY4XiZZRm\CCob4KgNUBpeiCob3zsc5dm\CCkeTDpdpJi\GmjdHnvckBw\iBzLkGzJItYN21{IGXWMYxq\2i2IH\vdkA2KG2rboOgcYVie3W{ZXSgZYZ1\XJiNEigbJJ{KHKnc3H6eZJqdiCjc4PhfS=>	NGDrenM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFE{Pyd-Mke3O\|QyOzd:L3G+
SK-MEL-28	NHHUPJZEgXSxdH;4bYNqfHliYYPzZZk>		NITPR2k1QCCq		MUnDfZRwe3SjdHnjJIFkfGm4aYT5JIlvKGi3bXHuJHNMNU2HTD2yPEBk\WyuczDoZZJjd3KrbnegRnJCTiCYNkCwSUBufXSjboSgZZQhOSCjbnSgN\|AhfU1ibXXhd5Vz\WRiYX\0[ZIhPDhiaILzJJJme2G8dYLpckBie3OjeR?=	NWfmR5FqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOzdpPkK3O\|c1OTN5PD;hQi=>
DAOY	MVrQdolu[XK7IIPjdoVmdiCjc4PhfS=>				NX;TZmZKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	NEeyeGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NEPUSHdRemmvYYL5JJNkemWnbjDhd5NigQ>?				MoTVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NETBO4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MoDuVJJqdWG{eTDzZ5Jm\W5iYYPzZZk>				MmjwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

体内研究

Dabrafenib（口服）抑制B-RafV600E突变的黑色素瘤（A375P）的生长，在免疫受损小鼠中皮下注射结肠癌（Colo205），Dabrafenib（口服）同样能抑制肿瘤生长。 ^[1]

参考文献

溶解度 (25°C)

体外	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+45% PEG 300+2% Tween 80+ddH2O	5 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dabrafenib (GSK2118436) SDF

分子量	519.56
化学式	C₂₃H₂₀F₃N₅O₂S₂
CAS号	1195765-45-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04547946	Not yet recruiting	Drug: dabrafenib + trametinib	Malignant Melanoma	Novartis Pharmaceuticals\|Novartis	January 29 2021	--
NCT04666272	Not yet recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma	Novartis Pharmaceuticals\|Novartis	December 22 2020	--
NCT04452877	Recruiting	Drug: Dabrafenib\|Drug: Trametinib	Carcinoma Non-Small-Cell Lung	Novartis Pharmaceuticals\|Novartis	August 19 2020	Phase 2
NCT04059224	Recruiting	Drug: Trametinib\|Drug: Dabrafenib	Stage IV Melanoma\|Stage III Melanoma	Universitair Ziekenhuis Brussel	January 28 2019	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

泛Raf抑制剂

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA批准的Raf抑制剂

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
最新的Raf抑制剂

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

研究领域

产品类型

定制您的化合物库

Dabrafenib (GSK2118436)

客户使用Selleck生产的Dabrafenib (GSK2118436)发表文献170篇：

产品安全说明书

Raf抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Dabrafenib (GSK2118436) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

相关Raf产品